Physician profile
Ashwin Babuji
NPI 1205401551
$1,652.89
in general payments reported to CMS, 2019-2025
15 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $145 · 2023: $400 · 2024: $632 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $626.01 | 2023-2024 | Otezla, Krystexxa, Repatha |
| Novo Nordisk INC | $182.35 | 2024-2025 | |
| Myovant Sciences INC. | $127.82 | 2022 | |
| Abbvie INC. | $124.74 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $122.85 | 2023 | Rexulti |
| Dexcom, INC. | $106.56 | 2021 | |
| Neurocrine Biosciences, INC. | $102.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $95.94 | 2021 | |
| Horizon Therapeutics Plc | $40.76 | 2023 | Krystexxa |
| Ucb, INC. | $26.06 | 2024 | Briviact |
| Hologic Sales and Service, LLC | $23.86 | 2025 | Aptima |
| Astrazeneca Pharmaceuticals LP | $22.70 | 2025 | Breztri |
| Glaxosmithkline, LLC. | $18.42 | 2023 | Arexvy |
| Organon LLC | $16.82 | 2022 | |
| Axsome Therapeutics, INC. | $15.92 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Babuji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.